-
1
-
-
0001530185
-
Daunomycin: a new antibiotic of the rhodomycin group
-
Di Marco A, Gaetani M, Dorigotti L, et al.: Daunomycin: a new antibiotic of the rhodomycin group. Nature 1964, 201:706. DOI: 10.1038/201706a0
-
(1964)
Nature
, vol.201
, pp. 706
-
-
Di Marco, A.1
Gaetani, M.2
Dorigotti, L.3
-
2
-
-
85131871192
-
Second generation anthracyclines
-
Muggia FM, Young CW, Carter SK, (eds), Martinus Nijhoff Publishers, The Hague
-
Mathe G, Maral R: Second generation anthracyclines. In Anthracycline Antibiotics in Cancer Therapy. (Developments in Oncology, 10). Edited by Muggia FM, Young CW, Carter SK. The Hague: Martinus Nijhoff Publishers; 1982:190–204.
-
(1982)
Anthracycline Antibiotics in Cancer Therapy. (Developments in Oncology, 10)
, pp. 190-204
-
-
Mathe, G.1
Maral, R.2
-
3
-
-
0014473575
-
Adriamycin (NSC-123, 127): a new antibiotic with antitumor activity
-
PID: 5772652
-
Di Marco A, Gaetani M, Scarpinato BM: Adriamycin (NSC-123, 127): a new antibiotic with antitumor activity. Cancer Chemother Rep 1969, 53:33–37.
-
(1969)
Cancer Chemother Rep
, vol.53
, pp. 33-37
-
-
Di Marco, A.1
Gaetani, M.2
Scarpinato, B.M.3
-
4
-
-
0014730847
-
Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151)
-
PID: 5527012, COI: 1:CAS:528:DyaE3cXhtF2rs70%3D
-
Sandberg JS, Howsden FL, Di Marco A, Goldin A: Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151). Cancer Chemother Rep 1970, 54:1–7.
-
(1970)
Cancer Chemother Rep
, vol.54
, pp. 1-7
-
-
Sandberg, J.S.1
Howsden, F.L.2
Di Marco, A.3
Goldin, A.4
-
5
-
-
0014865710
-
Phase I and preliminary phase II evaluation of Adriamycin (NSC123127)
-
PID: 5474180, COI: 1:CAS:528:DyaE3MXisVyl
-
Bonadonna G, Monfardini S, DeLena M, et al.: Phase I and preliminary phase II evaluation of Adriamycin (NSC123127). Cancer Res 1970, 30:2572–2582.
-
(1970)
Cancer Res
, vol.30
, pp. 2572-2582
-
-
Bonadonna, G.1
Monfardini, S.2
DeLena, M.3
-
6
-
-
0014066067
-
Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease
-
PID: 4290058, COI: 1:CAS:528:DyaF2sXosVKgug%3D%3D
-
Tan C, Tasaka H, Yu KP, et al.: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Cancer 1967, 20:333–353. DOI: 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K
-
(1967)
Cancer
, vol.20
, pp. 333-353
-
-
Tan, C.1
Tasaka, H.2
Yu, K.P.3
-
7
-
-
0014143917
-
Traitement des leucemies aigues granulocytaires par la rubidomycine [in French]
-
COI: 1:STN:280:CCeB3szkvFI%3D
-
Boiron M, Jacquillat C, Weil M, et al.: Traitement des leucemies aigues granulocytaires par la rubidomycine [in French]. Pathol Biol (Paris) 1967, 15:921–924.
-
(1967)
Pathol Biol (Paris)
, vol.15
, pp. 921-924
-
-
Boiron, M.1
Jacquillat, C.2
Weil, M.3
-
8
-
-
0015990773
-
Adriamycin: a new anticancer drug with significant clinical activity
-
PID: 4590654, COI: 1:CAS:528:DyaE2cXht1Oqtrw%3D
-
Blum R, Carter SK: Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 1974, 80:249–259.
-
(1974)
Ann Intern Med
, vol.80
, pp. 249-259
-
-
Blum, R.1
Carter, S.K.2
-
9
-
-
0018199537
-
Adriamycin and other anthracycline antibiotics under study in the United States
-
Carter SK, Umezawa H, Douros J, Sakurai Y, (eds), Springer-Verlag, Berlin
-
Benjamin RS: Adriamycin and other anthracycline antibiotics under study in the United States. In Antitumor Antibiotics (Recent Results in Cancer Research, 60). Edited by Carter SK, Umezawa H, Douros J, Sakurai Y. Berlin: Springer-Verlag,; 1978:230–240.
-
(1978)
Antitumor Antibiotics (Recent Results in Cancer Research, 60)
, pp. 230-240
-
-
Benjamin, R.S.1
-
10
-
-
0016959239
-
Lipid vesicles as carriers for introducing materials into cultured cells: influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells
-
PID: 818640, COI: 1:CAS:528:DyaE28XktFyhsL0%3D
-
Poste G, Papahadjopoulos D: Lipid vesicles as carriers for introducing materials into cultured cells: influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells. Proc Natl Acad Sci U S A 1976, 73:1603–1607. DOI: 10.1073/pnas.73.5.1603
-
(1976)
Proc Natl Acad Sci U S A
, vol.73
, pp. 1603-1607
-
-
Poste, G.1
Papahadjopoulos, D.2
-
11
-
-
85131901510
-
Pharmacologic and therapeutic characteristics of anthracycline liposome preparation
-
Muggia FM, Young CW, Carter SK, (eds), Martinus Nijhoff Publishers, The Hague
-
Rahman A, Goldin A, Schein P: Pharmacologic and therapeutic characteristics of anthracycline liposome preparation. In Anthracycline Antibiotics in Cancer Therapy. (Developments in Oncology, 10). Edited by Muggia FM, Young CW, Carter SK. The Hague: Martinus Nijhoff Publishers; 1982:254–273.
-
(1982)
Anthracycline Antibiotics in Cancer Therapy. (Developments in Oncology, 10)
, pp. 254-273
-
-
Rahman, A.1
Goldin, A.2
Schein, P.3
-
12
-
-
85131874599
-
Alternative methods of drug delivery
-
Muggia FM, Young CW, Carter SK, (eds), Martinus Nijhoff Publishers, The Hague
-
Rogers KE, Forssen EA, Tokes ZA: Alternative methods of drug delivery. In Anthracycline Antibiotics in Cancer Therapy (Developments in Oncology, 10). Edited by Muggia FM, Young CW, Carter SK. The Hague: Martinus Nijhoff Publishers; 1982:282–291.
-
(1982)
Anthracycline Antibiotics in Cancer Therapy (Developments in Oncology, 10)
, pp. 282-291
-
-
Rogers, K.E.1
Forssen, E.A.2
Tokes, Z.A.3
-
13
-
-
0025369344
-
A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin
-
PID: 2348224, COI: 1:STN:280:By%2BB2s%2FptV0%3D
-
Rahman A, Treat J, Roth JK, et al.: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990, 8:1093–1100.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1093-1100
-
-
Rahman, A.1
Treat, J.2
Roth, J.K.3
-
14
-
-
0025611112
-
Antitumor activity of liposome encapsulated in doxorubicin in advanced breast cancer: a phase II study
-
PID: 2231759, COI: 1:STN:280:By6D3sbjvVU%3D
-
Treat J, Greenspan A, Forst D, et al.: Antitumor activity of liposome encapsulated in doxorubicin in advanced breast cancer: a phase II study. J Natl Cancer Inst 1990, 82:1706–1710. DOI: 10.1093/jnci/82.21.1706
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 1706-1710
-
-
Treat, J.1
Greenspan, A.2
Forst, D.3
-
15
-
-
0017613830
-
Thrombophlebitic potential of intravenous cytotoxic agents
-
Henney JE, Von Hoff DD, Rozencweig M, Muggia FM: Thrombophlebitic potential of intravenous cytotoxic agents. Drug Intell Clin Pharmacol 1977, 11:266–267.
-
(1977)
Drug Intell Clin Pharmacol
, vol.11
, pp. 266-267
-
-
Henney, J.E.1
Von Hoff, D.D.2
Rozencweig, M.3
Muggia, F.M.4
-
18
-
-
0027267901
-
Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity
-
PID: 8334677, COI: 1:CAS:528:DyaK3sXlvFCqurs%3D
-
Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993, 19:197–228. DOI: 10.1016/0305-7372(93)90036-Q
-
(1993)
Cancer Treat Rev
, vol.19
, pp. 197-228
-
-
Launchbury, A.P.1
Habboubi, N.2
-
19
-
-
0021745628
-
Potential of liposomes to ameliorate anthracyccline-induced cardiotoxicity
-
PID: 6594763, COI: 1:CAS:528:DyaL2MXhtF2msrs%3D
-
Rahman A, Fumagalli A, Goodman A, Schein PS: Potential of liposomes to ameliorate anthracyccline-induced cardiotoxicity. Semin Oncol 1984, 11(suppl 3):45–48.
-
(1984)
Semin Oncol
, vol.11
, pp. 45-48
-
-
Rahman, A.1
Fumagalli, A.2
Goodman, A.3
Schein, P.S.4
-
21
-
-
0022858683
-
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS
-
Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986, 56:6387–6392.
-
(1986)
Cancer Res
, vol.56
, pp. 6387-6392
-
-
Matsumura, Y.1
Maeda, H.2
-
22
-
-
0028920270
-
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin
-
PID: 7707129, COI: 1:STN:280:ByqB383jtlU%3D
-
Gill PS, Espina BM, Muggia F, et al.: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995, 13:996–1003.
-
(1995)
J Clin Oncol
, vol.13
, pp. 996-1003
-
-
Gill, P.S.1
Espina, B.M.2
Muggia, F.3
-
23
-
-
0028054331
-
Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome)
-
PID: 7860226, COI: 1:STN:280:ByqC28vht1U%3D
-
Guaglianone P, Chan K, DelaFlor-Weiss E, et al.: Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 1994, 12:103–110. DOI: 10.1007/BF00874439
-
(1994)
Invest New Drugs
, vol.12
, pp. 103-110
-
-
Guaglianone, P.1
Chan, K.2
DelaFlor-Weiss, E.3
-
24
-
-
0028349925
-
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
-
PID: 8313389, COI: 1:CAS:528:DyaK2cXhslegs70%3D
-
Gabizon A, Catane R, Uziely B, et al.: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54:987–992.
-
(1994)
Cancer Res
, vol.54
, pp. 987-992
-
-
Gabizon, A.1
Catane, R.2
Uziely, B.3
-
25
-
-
0027315072
-
Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)
-
PID: 8504422, COI: 1:STN:280:ByyB2sfmsl0%3D
-
Cowens JW, Creaven PJ, Greco WR, et al.: Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993, 53:2796–2802.
-
(1993)
Cancer Res
, vol.53
, pp. 2796-2802
-
-
Cowens, J.W.1
Creaven, P.J.2
Greco, W.R.3
-
26
-
-
1842329793
-
Liposomal annamycin. Phase I clinical and pharmacological study [abstract]
-
Booser D, Esparza-Guerra L, Zou Y, et al.: Liposomal annamycin. Phase I clinical and pharmacological study [abstract]. Proc ASCO 1997, 16:762.
-
(1997)
Proc ASCO
, vol.16
, pp. 762
-
-
Booser, D.1
Esparza-Guerra, L.2
Zou, Y.3
-
27
-
-
0020654390
-
Tumor imaging potental of liposomes loaded with In-111-NTA: biodistribution in mice
-
Proffit RT, Williams LE, Presant CA, et al.: Tumor imaging potental of liposomes loaded with In-111-NTA: biodistribution in mice. J Nucl Med 1983, 24:45–51.
-
(1983)
J Nucl Med
, vol.24
, pp. 45-51
-
-
Proffit, R.T.1
Williams, L.E.2
Presant, C.A.3
-
28
-
-
0030024958
-
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma
-
PID: 8932544, COI: 1:CAS:528:DyaK28Xhs1egt7s%3D
-
Northfelt DW, Martin FJ, Working P, et al.: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996, 36:55–63.
-
(1996)
J Clin Pharmacol
, vol.36
, pp. 55-63
-
-
Northfelt, D.W.1
Martin, F.J.2
Working, P.3
-
29
-
-
0032945306
-
Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer: TLC D-99 Study Group
-
PID: 10334528, COI: 1:CAS:528:DyaK1MXjsF2ms78%3D, A key paper demonstrating the limitation of dose-intensifying classical liposomes
-
Shapiro CL, Ervin T, Welles L, et al.: Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer: TLC D-99 Study Group. J Clin Oncol 1999, 17:1435–1441. A key paper in demonstrating the limitation of dose-intensifying classical liposomes.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1435-1441
-
-
Shapiro, C.L.1
Ervin, T.2
Welles, L.3
-
30
-
-
0023689097
-
Treatment of epidemic Kaposi’s sarcoma with a combination of interferonalpha-2b and etoposide
-
COI: 1:STN:280:BiaD3M%2FotFM%3D
-
Krigel RL, Slywotzky CM, Lonberg M, et al.: Treatment of epidemic Kaposi’s sarcoma with a combination of interferonalpha-2b and etoposide. J Biol Respir Modif 1988, 7:359–364.
-
(1988)
J Biol Respir Modif
, vol.7
, pp. 359-364
-
-
Krigel, R.L.1
Slywotzky, C.M.2
Lonberg, M.3
-
31
-
-
9444258072
-
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma
-
PID: 8708728, COI: 1:CAS:528:DyaK28XltFSqtrw%3D
-
Gill PS, Wernz J, Scadden DT, et al.: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996, 14:2353–2364.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2353-2364
-
-
Gill, P.S.1
Wernz, J.2
Scadden, D.T.3
-
32
-
-
0030731376
-
Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi’s sarcoma
-
Northfelt DW: Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi’s sarcoma. Oncology 1997, 10(suppl 11):21–32.
-
(1997)
Oncology
, vol.10
, pp. 21-32
-
-
Northfelt, D.W.1
-
33
-
-
0000071980
-
Patients with advanced AIDS-related Kaposi’s sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy [abstract]
-
Volm MD, Wernz J: Patients with advanced AIDS-related Kaposi’s sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy [abstract]. Proc ASCO 1997, 16:46a.
-
(1997)
Proc ASCO
, vol.16
, pp. 46a
-
-
Volm, M.D.1
Wernz, J.2
-
34
-
-
0032759911
-
AIDS-related Kaposi’s sarcoma: a phase II study of liposomal doxorubicin: the TLC D-99 Study Group
-
PID: 10589755, COI: 1:CAS:528:DyaK1MXotV2gsLk%3D
-
Cheung TW, Remick SC, Azarnia N, et al.: AIDS-related Kaposi’s sarcoma: a phase II study of liposomal doxorubicin: the TLC D-99 Study Group. Clin Cancer Res 1999, 5:3432–3437.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 3432-3437
-
-
Cheung, T.W.1
Remick, S.C.2
Azarnia, N.3
-
35
-
-
0032895785
-
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
-
PID: 10334527, COI: 1:CAS:528:DyaK1MXjsF2ms74%3D
-
Valero V, Buzdar AU, Theriault RL, et al.: Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 1999, 17:1425–1434.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1425-1434
-
-
Valero, V.1
Buzdar, A.U.2
Theriault, R.L.3
-
36
-
-
85131887875
-
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial
-
Ranson MR, Carmichael J, O’Byrne J, et al.: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1996, 15:1385–1391.
-
(1996)
J Clin Oncol
, vol.15
, pp. 1385-1391
-
-
Ranson, M.R.1
Carmichael, J.2
O’Byrne, J.3
-
37
-
-
0034284335
-
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
-
A key paper linking pharmacology to specific toxicities observed with varied schedules of Doxil
-
Lyass O, Uziely B, Ben-Yosef M, et al.: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1027–1047. A key paper linking pharmacology to specific toxicities observed with varied schedules of Doxil. DOI: 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
-
(2000)
Cancer
, vol.89
, pp. 1027-1047
-
-
Lyass, O.1
Uziely, B.2
Ben-Yosef, M.3
-
38
-
-
0034129380
-
Paclitaxel and cisplatin in ovarian cancer [letter]
-
PID: 10829060, COI: 1:STN:280:DC%2BD3c3ptFahtA%3D%3D
-
Torri V, Harper PG, Colombo N, et al.: Paclitaxel and cisplatin in ovarian cancer [letter]. J Clin Oncol 2000, 18:2349.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2349
-
-
Torri, V.1
Harper, P.G.2
Colombo, N.3
-
39
-
-
0024523832
-
A Phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer
-
PID: 2712114, COI: 1:STN:280:BiaB38rps1I%3D
-
Delgado G, Potkul RK, Treat JA, et al.: A Phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol 1989, 160:812–817.
-
(1989)
Am J Obstet Gynecol
, vol.160
, pp. 812-817
-
-
Delgado, G.1
Potkul, R.K.2
Treat, J.A.3
-
40
-
-
0031055830
-
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation
-
This is the original description of the activity of Doxil ovarian cancer, using a phase II open-label design and standard criteria of response
-
Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1996, 15:987–993. This is the original description of the activity of Doxil in ovarian cancer, using a phase II open-label design and standard criteria of response.
-
(1996)
J Clin Oncol
, vol.15
, pp. 987-993
-
-
Muggia, F.M.1
Hainsworth, J.D.2
Jeffers, S.3
-
41
-
-
0033850066
-
Phase II study of liposomomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer
-
PID: 10963637, COI: 1:CAS:528:DC%2BD3cXntVCgsb4%3D
-
Gordon AN, Aranai CO, Rose PG, et al.: Phase II study of liposomomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000, 18:3093–3100.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3093-3100
-
-
Gordon, A.N.1
Aranai, C.O.2
Rose, P.G.3
-
42
-
-
0000388173
-
Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer [abstract]
-
Gordon AN, Fleagle JT, Parkin DE, et al.: Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer [abstract]. Proc ASCO 2000, 19:1504.
-
(2000)
Proc ASCO
, vol.19
, pp. 1504
-
-
Gordon, A.N.1
Fleagle, J.T.2
Parkin, D.E.3
-
43
-
-
0345504156
-
Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by coadministering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin
-
PID: 10585596, COI: 1:CAS:528:DC%2BD3cXhsVagsw%3D%3D, Report on a potentially important strategy to be utilized combination with liposomes
-
Krishna R, St-Louis M, Mayer LD: Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by coadministering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 2000, 85:131–141. Report on a potentially important strategy to be utilized in combination with liposomes. DOI: 10.1002/(SICI)1097-0215(20000101)85:1<131::AID-IJC23>3.0.CO;2-R
-
(2000)
Int J Cancer
, vol.85
, pp. 131-141
-
-
Krishna, R.1
St-Louis, M.2
Mayer, L.D.3
-
44
-
-
0007342552
-
Liposomal daunorubicin (Daunoxome) is active in the treatment of relapsed/refractory low-grade and intermediate-grade non-Hodgkin’s lymphoma (NHL) [abstract]
-
Tulpule A, Rarick MU, Kolitz J, et al.: Liposomal daunorubicin (Daunoxome) is active in the treatment of relapsed/refractory low-grade and intermediate-grade non-Hodgkin’s lymphoma (NHL) [abstract]. Blood 1998, 92(suppl 1):4036.
-
(1998)
Blood
, vol.92
, pp. 4036
-
-
Tulpule, A.1
Rarick, M.U.2
Kolitz, J.3
-
45
-
-
0033745652
-
A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL
-
PID: 10942057, COI: 1:STN:280:DC%2BD3MzgsVaquw%3D%3D
-
Flinn IW, Goodman SN, Post L, et al.: A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. Ann Oncol 2000, 11:691–695. DOI: 10.1023/A:1008361914894
-
(2000)
Ann Oncol
, vol.11
, pp. 691-695
-
-
Flinn, I.W.1
Goodman, S.N.2
Post, L.3
-
46
-
-
0032434667
-
Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma
-
PID: 10065112, COI: 1:STN:280:DyaK1M7msVGjtA%3D%3D
-
Pratt G, Wiles ME, Rawstrom AC, et al.: Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma. Hematol Oncol 1998, 16:47–55. DOI: 10.1002/(SICI)1099-1069(199806)16:2<47::AID-HON622>3.0.CO;2-3
-
(1998)
Hematol Oncol
, vol.16
, pp. 47-55
-
-
Pratt, G.1
Wiles, M.E.2
Rawstrom, A.C.3
-
47
-
-
0033911315
-
Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin
-
PID: 10607318, COI: 1:STN:280:DC%2BD3c%2Fot1yqtQ%3D%3D
-
Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000, 42:40–46. DOI: 10.1016/S0190-9622(00)90007-0
-
(2000)
J Am Acad Dermatol
, vol.42
, pp. 40-46
-
-
Wollina, U.1
Graefe, T.2
Karte, K.3
-
48
-
-
0031795043
-
A phase II study of doxil (lipsomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas
-
PID: 9834828, COI: 1:STN:280:DyaK1M%2FltFyqsQ%3D%3D
-
Garcia AA, Kempf RA, Rogers M, Muggia FM: A phase II study of doxil (lipsomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 1998, 9:1131–1133. DOI: 10.1023/A:1008439013169
-
(1998)
Ann Oncol
, vol.9
, pp. 1131-1133
-
-
Garcia, A.A.1
Kempf, R.A.2
Rogers, M.3
Muggia, F.M.4
-
49
-
-
0033626288
-
Caelyx in malignant mesothelioma: a phase II EORTC study
-
PID: 10942058, COI: 1:STN:280:DC%2BD3MzgsVejsg%3D%3D
-
Baas P, van Meerbeeck J, Groen H, et al.: Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000, 11:697–700. DOI: 10.1023/A:1008346925273
-
(2000)
Ann Oncol
, vol.11
, pp. 697-700
-
-
Baas, P.1
van Meerbeeck, J.2
Groen, H.3
-
50
-
-
0029038996
-
Liposomal doxorubicin: antitumor activity and unique toxicity during two complementary phase I studies
-
PID: 7602367, COI: 1:STN:280:ByqA38rovFw%3D
-
Uziely B, Jeffers S, Isaacson R, et al.: Liposomal doxorubicin: antitumor activity and unique toxicity during two complementary phase I studies. J Clin Oncol 1995, 13:1777–1785.
-
(1995)
J Clin Oncol
, vol.13
, pp. 1777-1785
-
-
Uziely, B.1
Jeffers, S.2
Isaacson, R.3
-
51
-
-
0033802643
-
Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
-
Safra T, Muggia F, Jeffers S, et al.: Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000, 11:1–5. DOI: 10.1023/A:1008365716693
-
(2000)
Ann Oncol
, vol.11
, pp. 1-5
-
-
Safra, T.1
Muggia, F.2
Jeffers, S.3
|